Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure - Trial NCT06336954
Access comprehensive clinical trial information for NCT06336954 through Pure Global AI's free database. This Phase 2 trial is sponsored by Second Affiliated Hospital of Xi'an Jiaotong University and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Second Affiliated Hospital of Xi'an Jiaotong University
Timeline & Enrollment
Phase 2
Mar 30, 2024
Dec 31, 2026
Primary Outcome
Progression-free survival time (PFS)
Summary
This prospective, single-arm trial explores the efficacy of Adibelimab monoclonal antibody
 combined with Famitinib and chemotherapy in treating locally advanced or metastatic NSCLC
 patients with negative driver genes who have progressed after PD-1 monoclonal antibody and
 chemotherapy treatment. The study focuses on assessing progression-free survival (PFS) in 40
 participants. Key objectives include evaluating PFS and understanding the progression
 patterns post-first-line immunotherapy, with an interest in whether switching from PD-1 to
 PD-L1 inhibitors can overcome immune resistance.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336954
Non-Device Trial